Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.39 | N/A | +133.05% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.39 | N/A | +133.05% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's future prospects. They highlighted the positive EPS surprise as a sign of solid underlying performance.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They emphasized ongoing efforts in research and development to drive future growth.
The earnings report shows that Alnylam Pharmaceuticals had a strong EPS performance, exceeding expectations significantly. However, the stock reacted negatively, declining by 2.62%. This decline may reflect investor concerns over the lack of revenue data and guidance, which can create uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 5, 2014